Issues for new antiepilepsy drug development

Current Opinion in Neurology

Volumn 26, Issue 2, 2013, Pages 195-200

  Simonato, Michele ^a,b   French, Jacqueline A ^c   Galanopoulou, Aristea S ^d   O'Brien, Terence J ^e  

^a UNIVERSITY OF FERRARA   (Italy)

^b National Institute of Neuroscience   (Italy)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

antiepileptogenesis; antiseizure drug; biomarker; comorbidity; disease modification

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; FLUROTHYL; KAINIC ACID; PILOCARPINE;

CLINICAL TRIAL (TOPIC); CLONIC SEIZURE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG HALF LIFE; EPILEPSY; EPILEPTIC STATE; FEBRILE CONVULSION; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SEIZURE; STUDY DESIGN; TRAUMATIC BRAIN INJURY;

CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; EPILEPSY; HUMANS;

EID: 84874941208     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32835efe29     Document Type: Review

References (27)

1. Loscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011; 52:657-678.
2. Galanopoulou AS, Buckmaster PS, Staley KJ, et al. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 2012; 53:571-582.
3. The NIH/NINDS Anticonvulsant Screening Program (ASP): recommendations from the working group's 2012 review of the Program. Epilepsia 2012; 53:1837-1839.
4. Simonato M, Lö scher W, Cole AJ, et al. Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia 2012; 53:1860-1867.
5. Goodkin HP, Sun C, Yeh JL, et al. GABA(A) receptor internalization during seizures. Epilepsia 2007; 48 (Suppl. 5):109-113.
6. Brooks-Kayal AR. Rearranging receptors. Epilepsia 2005; 46 (Suppl. 7):29-38. (Pubitemid 44914759)
7. Isaeva E, Isaev D, Khazipov R, et al. Long-term suppression of GABAergic activity by neonatal seizures in rat somatosensory cortex. Epilepsy Res 2009; 87:286-289.
8. Pekcec A, Unkrü er B, Stein V, et al. Over-expression of P-glycoprotein in the canine brain following spontaneous status epilepticus. Epilepsy Res 2009; 83:144-151.
9. Eyal S, Lamb JG, Smith-Yockman M, et al. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br J Pharmacol 2006; 149:250-260. (Pubitemid 44453425)
10. Dudek FE, Staley KJ. The time course of acquired epilepsy: implications for therapeutic intervention to suppress epileptogenesis. Neurosci Lett 2011; 497:240-246.
11. Buckmaster PS, Lew FH. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J Neurosci 2011; 31:2337-2347.
12. Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 2009; 29:6964-6972.
13. Raffo E, Coppola A, Ono T, et al. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol Dis 2011; 43:322-329.
14. Bittigau P, Sifringer M, Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. Ann NY Acad Sci 2003; 993:103-114. (Pubitemid 36808438)
15. Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S. consensus report. Epilepsia 2010; 51:2175-2189.
16. Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004; 62:1668-1681. (Pubitemid 38661719)
17. Chudomelova L, Scantlebury MH, Raffo E, et al. Modeling new therapies for infantile spasms. Epilepsia 2010; 51 (Suppl. 3):27-33.
18. Coppola A, Moshe SL. Animal models. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. Amsterdam: Elsevier; 2012. pp. 63-98.
19. Landis SC, Amara SG, Asadullah K, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012; 490:187-191.
20. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 2011; 10:712-713.
21. Kimmelman J, Anderson JA. Should preclinical studies be registered? Nat Biotechnol 2012; 30:488-489.
22. Porter RJ, Baulac M, Nohria V. Clinical development of drugs for epilepsy: a review of approaches in the United States and Europe. Epilepsy Res 2010; 89:163-175.
23. Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol 2011; 10:961-968.
24. Friedman D, French JA. Clinical trials for therapeutic assessment of antiepileptic drugs in the 21st century: obstacles and solutions. Lancet Neurol 2012; 11:827-834.
25. French JA, Kryscio RJ. Active control trials for epilepsy: avoiding bias in headto-head trials. Neurology 2006; 66:1294-1295. (Pubitemid 43739631)
26. Schmidt D. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. Epileptic Disord 2012; 14:105-113.
27. Engel J Jr. Biomarkers in epilepsy: foreword. Biomarkers Med 2011; 5:529-530.